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Summary 
The kappa receptor-selective agonist U-50,488 was admini- 
stered chronically to rhesus monkeys. Tolerance developed to 
the overt behavioral effects of U-50,488 without cross- 
tolerance to morphine, withdrawal behaviors produced by 
deprivation, naloxone or quadazocine administration in U-50, 
488-dependent monkeys consisted of hyperactivity, excessive 
grooming, and yawning. The syndrome was suppressed in a 
dose-related manner by a kappa agonist, ethylketazocine, but 
not by doses of morphine that suppressed its own withdrawal. 
The mu-selective antagonist, beta-funaltrexamine, at doses 
which are active in morphine-dependent monkeys, did not precip- 
itate withdrawal in U50, 488-dependent monkeys. Dependence, 
which is the result of activity at the kappa receptor, was 
distinct frc~u morphine dependence. 
It has long been recognized that chronic administration of some types of 
opioids (e.g., nalorphine, pentazocine) results in dependence which is 
qualitatively unlike morphine dependence (1,2,3). The observation that mild 
and qualitatively different withdrawal syndromes developed following chronic 
injections of nalorphine led, in part, to the hypothesis of multiple opioid 
receptors (1). Only recently, however, have the pharmacological probes 
become available to permit the characterization of dependence that may occur 
through the stimulation of kappa receptors specifically. 
U-50,488 is a chemically novel opioid, and its kappa-receptor agonist 
profile may be demonstrated by the following characteristics: (a) it does 
not suppress withdrawal in morphlne-dependent monkeys (4), (b) the compound 
shares discriminative stimulus characteristics with ethylketazocine, but not 
with morphine, in rhesus monkeys (4,5), (c) in contrast with morphine, it is 
not self-administered at rates significantly greater than saline controls in 
rhesus monkeys (Dr. G. Winger, University of Michigan, personal 
communication) and rats (5), and (d) it causes diuresis in rats (6) and 
rhesus monkeys (5,7). The discriminative and diuretic effects of U-50,488 
are prevented by opioid antagonists as are its antinociceptive actions in a 
variety of rodent analgesic assays. Nevertheless, in the mouse tail-flick 
test, 36 times more naloxone was required to inhibit U-50,488 to an 
equivalent degree as morphine (8). 
U-58,488 has considerably greater relative affinity for kappa 
recognition sites than for other opioid binding sites. For example, U-50,488 
shows a 256-fold selectivity for kappa over mu or delta binding sites in 
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guinea pig brain homogenates (9), whereas dynorphin A (1-13) and 
ethylketazocine have selectivltles for kappa over mu sites of 11.3 and 1.8, 
respectively (IN). Based on the above observations, U-50,488 was chosen as 
having a potentlal for maintaining kappa receptor-selectlve stimulation 
during the administration of high doses for an extended period of time. 
Mice and rats treated chronically with U-50,488 have not shown signs of 
dependence upon abrupt withdrawal or naloxone challenge (5,8,11). Similarly, 
Aceto et al. (12) gave U-50,488 to rhesus monkeys for a period of 45 days and 
concluded that llttle morphlne-llke dependence developed. The question 
remained, however, if dependence of any type develops. Therefore, in the 
present investigation, dependence to U-50,488 was studied in further detail. 
Methods 
Six group-housed rhesus monkeys (Macaca mulatta) (4-5 kg) were given 
free access to food and fresh water daily, and to fresh fruit once weekly. 
They were trained to receive subcutaneous injections. 
U-50,488 (trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolldlnyl)-cyclohexyl)- 
benzeneacetamide methanesulfonate, hydrate; Dr. J. Collins, Upjohn Co) was 
administered s.c. at maximally tolerable (sedative but non-toxic) doses. As 
tolerance developed the dose was gradually increased from 0.3 mg/kg/6 hrs to 
17.5 mg/kg/4 hrs over 135 days (see Results). Testing with 
beta-funaltrexamine (8-FNA, Dr. D. Zim~erman, Lilly), (+) and (-) 
ethylketazoclne methanesulfonate (Dr. W. Michne, Sterling-Winthrop), morphine 
sulfate (Merck), naloxone HCl (Endo), quadazoclne (also known as Win 44,441, 
Dr. W. Michne) and U-50,488 occurred at weekly intervals. 
On test days, the appearance and behavior of the monkeys was monitored 
by two experienced observers familiar with the individual animals. Each 
monkey served as its own control. Injections with test substances began at 
10 am: prior to chronic U-50,488 administration, one hour after the last 
maintenance dose of U-50,488 in non-wlthdrawn monkeys, or 9 hrs after the 
last maintenance dose of U-5~,488 in withdrawn monkeys. Injections were 
given every 30 mln such that the total cumulative dose of the test agent 
increased by 1/4-1/2 log-unit with each injection. Muscle relaxation scores 
were assigned at 30 mln intervals corresponding with drug injections 
according to a modified Irwin Scale as described prevlously (13,14) such that 
higher scores were given to monkeys showing greater amounts of generalized 
muscle relaxation. For example, monkeys showing pronounced muscle 
relaxation, slack jaw and shoulder droop were assigned scores of "2". 
Withdrawal behavior was also quantified at 30 mln intervals. The number of 
bouts of scratching or grooming and the number of yawns, unusual tongue 
movements and wet-dog shakes dlsplayed by each monkey was counted during a 
5-min interval beginning 15-25 min after each injection. These numbers were 
averaged across all of the monkeys in the group. 
Results 
The dose of U-50,488 given chronically was increased as the severity and 
duration of stupor and muscle relaxation decreased. The dose regimen was 
changed as follows: days 1-6, 0.3 mg/kg/6 hrs; days 7-10, 0.56 mg/kg/6 hrs; 
days 11-18, 1.0 mg/kg/6 hrs; days 19-33, 3.0 mg/kg/6 hrs; days 34-54, 5.6 
mg/kg/6 hrs; days 55-68, 5.6 mg/kg/4 hrs; days 69-92, 10 mg/kg/4 hrs; and 
days 93-135, 17.5 mg/kg/4 hrs. 
Figure 1 shows the tolerance that developed to U-50,488-induced muscle 
relaxation. Prior to chronic U-50,488 injections, U-50,488 produced muscle 
relaxation in a dose-related manner in that with increasing doses, more 
animals showed higher levels of muscle relaxation. On day 92 of chronic 
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U-50,488 administration, 32 mg/kg U-50,488 did not produce muscle relaxation 
of scores > "2" in any of the monkeys, but caused pronounced stupor (i.e., a 
lack of response to moderate external stimuli) such that higher doses could 
not be tested. Thus, on day 92 there was a shift down of more than 2.5 
log-units relative to day 1 of chronic U-50,488 administration. 
Cross-tolerance to morphine-induced muscle relaxation did not occur in that 
there was no change in the morphine dose-effect curve on day 92 compared to 
the curve obtained prior to chronic U-50,488 administration. 
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FIG 1 
The effect of U-50,488 and morphine on muscle relaxatlon in 
monkeys receiving chronic injections of U-50,488. U-50,488 was 
given just prior to the first day of chronic administration 
(open circles; n=6) and on day 92 of chronic administration 
(closed circles; n=3). Morphine was given one week prior to 
the chronic administration of U-50,488 (open squares; n=6) and 
on day 92 of chronic U-50,488 administration (closed squares; 
n=3). 
At weekly intervals beginning on day 26 of chronic U-50,488 administra- 
tion, the monkeys were deprived of drug for up to 15 hours. Deprivation 
resulted in the following behaviors: hyperactivity; excessive grooming that 
included excessive scratching, grooming of cage-mates, and picking at fingers 
and toes; and yawning associated with unusual tongue movements (e.g., tongue 
rotated and twisted to the side of the mouth). These behaviors were observed 
on day 26 of chronic U-50,488 injections but withdrawal signs became more 
frequent and intense as the duration of U-50,488 administration increased. 
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Dependence reached an apparent steady state following approximately eight 
weeks of U-50,488 administration. The intensity and ntunber of these 
behaviors peaked 8-11 hrs after the last injection of U-50,488. There were 
no signs of irritability or abdominal defense reactions upon handling and 
palpation which are characteristic of morphine withdrawal. 
The monkeys were completely withdrawn from U-50,488 after 135 days of 
chronic administration. Withdrawal signs again peaked fol]~wlng 8-11 hrs of 
abstinence and were essentially absent by the third 6*y following drug 
termination. 
Figure 2 shows the suppression (panel a) and precipitation (panel b) of 
withdrawal in the U-50,488-dependent monkeys. The withdrawal signs observed 
in 9-hr deprived U-50,488-dependent monkeys were suppressed in a dose-related 
manner by U-50,488. The suppression of withdrawal by et~ylketaocine was ,]so 
dose-related and stereoselectlve in that (-)-ethylketazoclne was 10 times 
more potent than (+)-ethylketazocine in decreasing the number of withdrawal 
signs. Morphine partlally suppressed U-50,488 withdrawal signs only at doses 
which also caused pronounced stupor and muscle relaxation (i.e., 10 mg/kg; 
see Figure 1). This dose is sufficient to suppress completely a 
moderately-severe withdrawal syndrome in monkeys receiving 3 mg/kg/6 hr 
morphine. Withdrawal behaviors Indlstlngulshable from deprlvation-lnduced 
withdrawal were precipitated in a dose-related manner by naloxone and 
quadazocine in the U-50,488-dependent monkeys (panel 2b). 
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FIG 2 
The suppression (a) and precipitation (b) of withdrawal in 
U-50,488-dependent monkeys. (a) U-50,488 (n=6), morphine 
(n=6), (-)-ethylketazooine (EKC, n=3) and (+)-ethylketazoclne 
(n=3) were given cumulatively beginning 9 hrs after the last 
maintenance dose of U-50,488 on days 89, 96, and 113 of chronic 
administration, respectively. (b) Naloxone (n=6) and quadazo- 
clne (n=6) were given cumulatively beginning one hr after the 
last maintenance dose of U-50,488 on days 75 and 82 of chronic 
administration, respectively. P.I. = pre-lnjection. 
Beta-funaltrexamine (8-FNA) was given cumulatively at doses of 1-10 
mg/kg beginning one hr after the last maintenance dose of U-50,488 (day 62 of 
chronic administration). 8-FNA did not produce any signs of wlthdrawal, 
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although this dose will precipitate a moderately-severe, long-lasting 
withdrawal syndrome in morphine-dependent monkeys (3 mg/kg/6 hrs)(14). 
Discussion 
Chronic administration of U-50,488 resulted in tolerance to its overt 
behavioral effects without cross-tolerance to morphine. Similarly, in the 
mouse tail-flick test, multiple injections of U-50,488 over three days 
resulted in a 26-fold reduction in sensitivity to U-50,488 while the 
sensitivity to morphine changed only slightly (8). Thus, significant 
tolerance may develop to behavioral properties of U-50,488 with little or no 
cross-tolerance to an equivalent effect produced by morphine. 
Deprivation and antagonist-induced abstinence from U-50,488 resulted in 
a distinctive withdrawal syndrome. The signs observed during U-50,488 
withdrawal were behaviors that are not normally observed to occur to a 
significant extent in morphine-dependent monkeys (3,15). Morphine-dependent 
monkeys undergoing deprivation or antagonlst-induced withdrawal display 
behaviors associated with irritability and abdominal discomfort: avoidance of 
all contact with other monkeys, assuming postures which protect the abdomen, 
extreme irritability to touch, retching and vomiting, and a rigid abdomen 
when palpated. These signs were never detected in the U-50,488-dependent 
monkeys, either during deprivation or following antagonist administration. 
Quadazocine was approximately 10 times more potent than naloxone in 
precipitating U-50,488 withdrawal. In morphine-dependent monkeys, 
quadazocine was only about three times more potent than naloxone in 
precipitating withdrawal (unpublished observations). These results are in 
agreement with studies indicating that quadazocine has less mu-receptor 
selectivity than naloxone (16). However, these and other potency differences 
across antagonists are curious and need to be examined with other behavioral 
effects. For example, quadazooine has a 30-fold higher potency in reversing 
morphine compared to U-50,488 analgesic effects in monkeys (unpublished 
observations). 
An important criterion for inferring a state of dependence is to obtain 
similar signs both with deprivation of the agonist and with antagonist 
administration. U-50,488-withdrawal behavior indistigulshable from 
deprivation-induced withdrawal was precipitated by the opiold antagonists. 
Moreover, the suppression of U-50,488 withdrawal was stereoselective, with 
the (-) isomer of ethylketazocine being lO times more potent than the (+) 
isomer. 
Morphine did not suppress withdrawal in the U-50,488-dependent monkeys 
at non-sedative doses. At the doses used in the present study, morphine 
suppresses abstinence associated with its chronic administration (3 mg/kg/6 
hrs). Conversely, U-50,488 suppresses withdrawal signs in morphine-dependent 
monkeys only at doses which also produce severe stupor (4). The mu-selective 
antagonist 8-FNA (17) did not produce any withdrawal signs in the U-50,488- 
dependent monkeys up to a dose of 10 mg/kg. This dose of 8-FNA precipitates 
withdrawal equivalent to 14-hr abstinence in morphine-dependent monkeys (14). 
These data indicate that the precipitation and suppression of U-50,488 with- 
drawal may be selectively produced by antagonists and agonists, known in 
other assay systems, to be opioid receptor selective. Given these results, 
together with the considerable in vitro selectivlty of U-50,488, it is 
suggested that this form of dependence is produced by activation of the kappa 
receptor. 
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